友芝友生物-B(02496)发布中期业绩，净亏损5883.4万元，同比收窄25%

Core Viewpoint - The company reported a revenue of 37.187 million RMB for the six months ending June 30, 2025, with a net loss of 58.834 million RMB, which represents a 25% year-on-year reduction in losses [1] Revenue Breakdown - Revenue includes licensing fees and research and development (R&D) service income [1] - Licensing fee income primarily comes from a collaboration agreement with Zhengda Tianqing, generating 4.7 million RMB from milestone achievements related to the licensing rights [1] - R&D service income amounted to 32.5 million RMB, recognized based on the company's efforts and inputs relative to the total expected inputs required to fulfill contractual obligations under the collaboration agreement with Zhengda Tianqing [1]